China’s Tiotropium Bromide market – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:36 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg China’s Tiotropium Bromide market – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Tiotropium Bromide Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-tiotropium-bromide-market-2021-2025/ Thu, 27 May 2021 06:56:12 +0000 https://www.cri-report.com/?post_type=product&p=11657 According to CRI’s market research, the sales of Tiotropium Bromide in the Chinese market have been on the rise from 2016 to 2019.

The post Investigation Report on China’s Tiotropium Bromide Market 2021-2025 first appeared on CRI Report.

]]> Description
Tiotropium Bromide, developed by Boehringer Ingelheim International GmbH, is used to treat chronic obstructive pulmonary disease (COPD). Its product SPIRIVA was approved in China in 2006. In 2017, Tiotropium Bromide inhalation powder was included in the national medical insurance catalog. By the first half of 2021, in addition to Boehringer Ingelheim International GmbH, there are Nanchang Hongyi Pharmaceutical Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., and Zhejiang Xianju Pharmaceutical Co., Ltd. in China’s Tiotropium Bromide market.

According to CRI’s market research, the sales of Tiotropium Bromide in the Chinese market have been on the rise from 2016 to 2019. Especially after the inhalation powder of Tiotropium Bromide was included in the national medical insurance catalog in 2017, its sales have grown steadily from 2017 to 2019. However, its sales fell 19.3% year-on-year to CNY274 million in 2020. The main reason for the decline in its sales is that the COVID-19 epidemic has impacted the hospital’s overall diagnosis and treatment business. The CAGR of Tiotropium Bromide in the Chinese market from 2016 to 2020 is 4.73%.

CRI predicts that with the effective alleviation of the COVID-19 epidemic, the sales volume of Tiotropium Bromide in the Chinese market from 2021 to 2025 will have a restorative growth, promoting the increase in sales. As of the end of 2020, the number of chronic resistance disease patients in China has increased to more than 100 million. Therefore, the sales of Tiotropium Bromide will continue to grow, promoting the growth of the Tiotropium Bromide market.

Topics Covered:
-The impact of COVID-19 on China’s Tiotropium Bromide market
– Sales value of China’s Tiotropium Bromide 2016-2020
– Competitive landscape of China’s Tiotropium Bromide market
– Prices of Tiotropium Bromide in China
– Prices of Tiotropium Bromide in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Tiotropium Bromide market
– Prospect of China’s Tiotropium Bromide market from 2021 to 2025

The post Investigation Report on China’s Tiotropium Bromide Market 2021-2025 first appeared on CRI Report.

]]>